Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19 Still Dampens Neurocrine Revenues Despite Industry’s Q3 Uptick

A Pair Of Clinical Holds Hinders The Pipeline

Executive Summary

The pandemic has hit psychiatry offices hard, and the company’s management said it anticipates flat sequential revenues in Q4.

You may also be interested in...



Neurocrine Not Giving Up On Luvadaxistat Despite Phase II Miss

Schizophrenia drug licensed from Takeda missed Phase II endpoint for negative symptoms, but hits secondary cognition endpoints. Neurocrine plans to further study compound for cognitive benefits.

Neurocrine Will Delay Ongentys Launch, But It Thinks Differentiation Is Clear

Ongentys, now approved as adjunctive therapy in Parkinson’s disease, will offer a convenience advantage over generic COMT inhibitors. The company will delay launch due to pandemic and manufacturing issues.

BioMarin Rolls Up Sleeves To Prepare For Roctavian’s EU Debut

The company plans to start in Germany with an outcomes-based payment model. But while a US FDA nod seems likely, analysts have been more cautious about calling US approval a done deal.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC143291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel